Advanced Solidstate Array Spectroradiometer

During the Summer of 1987, the Advanced Solidstate Array Spectroradiometer (ASAS) was installed and flown on the NASA Ames C-130 in support of the First International Field Experiment (FIFE) missions. The study site was over the grassland areas of the Konza Prairie in Kansas. The data collected with ASAS during these flights has been used to produce the first nearly simultaneous multiangular/multispectral images of selected terrestrial study sites. This data will be valuable in the study of surface bidirectional reflectance and albedo. The data will also be useful for the development of data analysis algorithms for future spaceborne instruments such as the Goddard MODIS-T and JPL's HIRIS. The flight data acquired is further analyzed

Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol

$\textbf{Introduction:}$ Despite therapeutic advances, many individuals with type 1 diabetes are unable to achieve tight glycaemic target without increasing the risk of hypoglycaemia. The objective of this study is to determine the effectiveness of a 3-month day-and-night home closed-loop glucose control combined with a pump suspend feature, compared with sensor-augmented insulin pump therapy in youths and adults with suboptimally controlled type 1 diabetes. $\textbf{Methods and analysis:}$ The study adopts an open-label, multi-centre, multi-national (UK and USA), randomised, single-period, parallel design and aims for 84 randomised patients. Participants are youths (6-21 years) or adults (>21 years) with type 1 diabetes treated with insulin pump therapy and suboptimal glycaemic control (glycated haemoglobin (HbA1c) ≥7.5% (58 mmol/mol) and ≤10% (86 mmol/mol)). Following a 4-week run-in period, eligible participants will be randomised to a 3-month use of automated closed-loop insulin delivery combined with pump suspend feature or to sensor-augmented insulin pump therapy. Analyses will be conducted on an intention-to-treat basis. The primary outcome is the time spent in the target glucose range from 3.9 to 10.0 mmol/L based on continuous glucose monitoring levels during the 3-month free-living phase. Secondary outcomes include HbA1c at 3 months, mean glucose, time spent below and above target; time with glucose levels 16.7 mmol/L, glucose variability; total, basal and bolus insulin dose and change in body weight. Participants' and their families' perception in terms of lifestyle change, daily diabetes management and fear of hypoglycaemia will be evaluated. $\textbf{Ethics and dissemination:}$ Ethics/institutional review board approval has been obtained. Before screening, all participants/guardians will be provided with oral and written information about the trial. The study will be disseminated by peer-reviewed publications and conference presentations. $\textbf{Trial registration number:}$ NCT02523131; Pre-results.JDRF, National Institute for Health Research Cambridge Biomedical Research Centre, Wellcome Strategic Award (100574/Z/12/Z)

Hereditary multiple exostoses and solitary osteochondroma associated with growth hormone deficiency: to treat or not to treat?

BACKGROUND: Osteochondroma generally occurs as a single lesion and it is not a heritable disease. When two or more osteochondroma are present, this condition represents a genetic disorder named hereditary multiple exostoses (HME). Growth hormone deficiency (GHD) has rarely been found in HME patients and a few data about growth therapy (GH) therapy effects in development/growth of solitary or multiple exostoses have been reported. CASE PRESENTATION: We describe the clinical features of 2 patients (one with osteochondroma and one with HME) evaluated before and after GH therapy. In the first patient, the single osteochondroma was noticed after the start of treatment; the other patient showed no evidence of significant increase in size or number of lesions related to GH therapy. CONCLUSION: It is necessary to investigate GH secretion in patients with osteochondroma or HME and short stature because they could benefit from GH replacement therapy. Moreover, careful clinical and imaging follow-up of exostoses is mandatory

Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry

OBJECTIVES: The Digital Ulcers Outcome (DUO) Registry was designed to describe the clinical and antibody characteristics, disease course and outcomes of patients with digital ulcers associated with systemic sclerosis (SSc). METHODS: The DUO Registry is a European, prospective, multicentre, observational, registry of SSc patients with ongoing digital ulcer disease, irrespective of treatment regimen. Data collected included demographics, SSc duration, SSc subset, internal organ manifestations, autoantibodies, previous and ongoing interventions and complications related to digital ulcers. RESULTS: Up to 19 November 2010 a total of 2439 patients had enrolled into the registry. Most were classified as either limited cutaneous SSc (lcSSc; 52.2%) or diffuse cutaneous SSc (dcSSc; 36.9%). Digital ulcers developed earlier in patients with dcSSc compared with lcSSc. Almost all patients (95.7%) tested positive for antinuclear antibodies, 45.2% for anti-scleroderma-70 and 43.6% for anticentromere antibodies (ACA). The first digital ulcer in the anti-scleroderma-70-positive patient cohort occurred approximately 5 years earlier than the ACA-positive patient group. CONCLUSIONS: This study provides data from a large cohort of SSc patients with a history of digital ulcers. The early occurrence and high frequency of digital ulcer complications are especially seen in patients with dcSSc and/or anti-scleroderma-70 antibodies

HIV Integration Targeting: A Pathway Involving Transportin-3 and the Nuclear Pore Protein RanBP2

Genome-wide siRNA screens have identified host cell factors important for efficient HIV infection, among which are nuclear pore proteins such as RanBP2/Nup358 and the karyopherin Transportin-3/TNPO3. Analysis of the roles of these proteins in the HIV replication cycle suggested that correct trafficking through the pore may facilitate the subsequent integration step. Here we present data for coupling between these steps by demonstrating that depletion of Transportin-3 or RanBP2 altered the terminal step in early HIV replication, the selection of chromosomal sites for integration. We found that depletion of Transportin-3 and RanBP2 altered integration targeting for HIV. These knockdowns reduced HIV integration frequency in gene-dense regions and near gene-associated features, a pattern that differed from that reported for depletion of the HIV integrase binding cofactor Psip1/Ledgf/p75. MLV integration was not affected by the Transportin-3 knockdown. Using siRNA knockdowns and integration targeting analysis, we also implicated several additional nuclear proteins in proper target site selection. To map viral determinants of integration targeting, we analyzed a chimeric HIV derivative containing MLV gag, and found that the gag replacement phenocopied the Transportin-3 and RanBP2 knockdowns. Thus, our data support a model in which Gag-dependent engagement of the proper transport and nuclear pore machinery mediate trafficking of HIV complexes to sites of integration

CVD Tungsten and Tungsten-Rhenium Alloys for Structural Applications. Part 3. Recent Developments.

Results obtained since the Gatlinburg Conference on a continuing program to develop CVD tungsten and tungsten-rhenium alloy structures with mechanical properties comparable to those of wrought products are presented. New data relating the effects of all the plating parameters on the deposition rate, deposit composition, topography, microstructure, and mechanical properties, together with effects of various heat treatments on the microstructure and properties, are reviewed. New developments in CVD equipment and techniques are also included

Helium-cooled molten-salt fusion breeder

We present a new conceptual design for a fusion reactor blanket that is intended to produce fissile material for fission power plants. Fast fission is suppressed by using beryllium instead of uranium to multiply neutrons. Thermal fission is suppressed by minimizing the fissile inventory. The molten-salt breeding medium (LiF + BeF/sub 2/ + ThF/sub 4/) is circulated through the blanket and to the on-line processing system where /sup 233/U and tritium are continuously removed. Helium cools the blanket and the austenitic steel tubes that contain the molten salt. Austenitic steel was chosen because of its ease of fabrication, adequate radiation-damage lifetime, and low corrosion by molten salt. We estimate that a breeder having 3000 MW of fusion power will produce 6500 kg of /sup 233/U per year. This amount is enough to provide makeup for 20 GWe of light-water reactors per year or twice that many high-temperature gas-cooled reactors or Canadian heavy-water reactors. Safety is enhanced because the afterheat is low and blanket materials do not react with air or water. The fusion breeder based on a pre-MARS tandem mirror is estimated to cost $4.9B or 2.35 times a light-water reactor of the same power. The estimated cost of the /sup 233/U produced is$40/g for fusion plants costing 2.35 times that of a light-water reactor if utility owned or $16/g if government owned

Design of a helium-cooled molten salt fusion breeder

A new conceptual blanket design for a fusion reactor produces fissile material for fission power plants. Fission is suppressed by using beryllium, rather than uranium, to multiply neutrons and also by minimizing the fissile inventory. The molten-salt breeding media (LiF + BeF/sub 2/ + TghF/sub 4/) is circulated through the blanket and on to the online processing system where /sup 233/U and tritium are continuously removed. Helium cools the blanket including the steel pipes containing the molten salt. Austenitic steel was chosen because of its ease of fabrication, adequate radiation-damage lifetime, and low corrosion rate by molten salt. We estimate the breeder, having 3000 MW of fusion power, produces 6400 kg of /sup 233/U per year, which is enough to provide make up for 20 GWe of LWR per year (or 14 LWR plants of 4440 MWt) or twice that many HTGRs or CANDUs. Safety is enhanced because the afterheat is low and the blanket materials do not react with air or water. The fusion breeder based on a pre-MARS tandem mirror is estimated to cost $4.9B or 2.35 times an LWR of the same power. The estimated present value cost of the /sup 2/anumber/sup 3/U produced is$40/g if utility financed or $16/g if government financed